slide1 n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Evaluation of HCC Response to Systemic Therapy with Quantitative MRI (1 U01 CA172320-01) PowerPoint Presentation
Download Presentation
Evaluation of HCC Response to Systemic Therapy with Quantitative MRI (1 U01 CA172320-01)

Loading in 2 Seconds...

play fullscreen
1 / 1

Evaluation of HCC Response to Systemic Therapy with Quantitative MRI (1 U01 CA172320-01) - PowerPoint PPT Presentation


  • 171 Views
  • Uploaded on

Evaluation of HCC Response to Systemic Therapy with Quantitative MRI (1 U01 CA172320-01) Guido Jajmovich , Octavia Bane, Hadrien Dyvorne, Bachir Taouli; Icahn School of Medicine at Mount Sinai.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Evaluation of HCC Response to Systemic Therapy with Quantitative MRI (1 U01 CA172320-01)' - saxon


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

Evaluation of HCC Response to Systemic Therapy with Quantitative MRI (1 U01 CA172320-01)

Guido Jajmovich, Octavia Bane, Hadrien Dyvorne, Bachir Taouli; Icahn School of Medicine at Mount Sinai

Overall objective: Develop a quantitative multiparametric protocol combining measurements of MR diffusion, perfusion and hypoxia in hepatocellular carcinoma (HCC)

  • Objectives
  • Year 1
  • Develop a framework for quality control (QC) in functional MRI of the liver in patients with HCC
  • Determine reproducibility of diffusion, DCE-MRI and R2* metrics in HCC and liver parenchyma
  • Year 2
  • Develop a quantitative multiparametric scoring system combining measurements of MR diffusion, perfusion and hypoxia against histopathologic measures of tumor grade, cellularity, aggressiveness, angiogenesis and hypoxia in HCC.
  • Develop an advanced pathologic evaluation platform evaluating HCC tumor biology
  • Gain insight into intratumoral heterogeneity in MR metrics and pathology, and differentiate biological heterogeneity from image noise
  • Year 1 Summary Results
  • QC parameters being assessed: image quality, metrics variability, goodness of fit, quality of DCE-MRI curves, intra-patient test-retest, inter- and intra-observer variability, differences between 1.5T and 3T, assessment of pathologic variability.
  • Test-retest reproducibility in HCC
    • IVIM DWI: Mean CV (n=5) D (true diffusion coefficient) 19.8%, PF (perfusion fraction) 21.7%, D* (pseudodiffusion coefficient) 65.2%, and ADC 17.4%.
    • DCE-MRI: mean CV (n=12) Ktrans 38.2%, Ve 37.7%, Kep 52.7%
    • R2*: mean CV of R2* value with room air (n=8) 14.8%, under O2 (12.2%), carbogen (11.8%).

Multiparametric approach in HCC

Reference T2 HASTE, Time to Peak (TTP), slope, AUC60, D and ADC maps in a patient with a 14 cm HCC.

VIBE post-contrast R2* room air (sec-1) R2* O2 R2* CO2

HCC identified on post-contrast imaging (arrows) shows minimal response to O2 (R2* air 23.81 s-1, R2* O2 23.65 s-1) and a minimal increase in R2* with carbogen (R2* CO2 25.22 s-1).